Polymorphisms of delta-aminolevulinic acid dehydratase (ALAD) and peptide transporter 2 (PEPT2) genes in children with low-level lead exposure

NeuroToxicology

Volumn 30, Issue 6, 2009, Pages 881-887

  Sobin, Christina ^a,b   Gutierrez, Marisela ^a   Alterio, Heather ^a  

^a UNIVERSITY OF TEXAS AT EL PASO   (United States)

^b ROCKEFELLER UNIVERSITY   (United States)

Author keywords

ALAD2; Health disparities; Hispanic; Lead exposure; Minority health; Neurotoxicity; PEPT2

Indexed keywords

BIOLOGICAL MARKER; LEAD; PEPTIDE TRANSPORTER 2; PORPHOBILINOGEN SYNTHASE;

ARTICLE; CHILD; CHILDHOOD; COGNITIVE DEVELOPMENT; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DNA EXTRACTION; ENVIRONMENTAL EXPOSURE; ETHNIC DIFFERENCE; FEMALE; GENE MUTATION; GENETIC MARKER; GENETIC VARIABILITY; HETEROZYGOSITY; HIGH RISK POPULATION; HISPANIC; HOMOZYGOSITY; HUMAN; HUMAN CELL; LEAD BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NEUROTOXICITY; PRIORITY JOURNAL; PROTEIN POLYMORPHISM;

EID: 71249161521     PISSN: 0161813X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuro.2009.08.006     Document Type: Article

References (44)

1. Agency of Toxic Substances and Disease Registry; 2004.
2. Battistuzzi G., Petrucci R., Silvagni L., Urbani F.R., and Caiola S. delta-Aminolevulinate dehydrase: a new genetic polymorphism in man. Ann Hum Genet 45 (1981) 223-229
3. Benkman H.G., Gogdaanski P., and Goedde H.W. Polymorphism of delta-aminolevulinic acid dehydratase in various populations. Human Hered 33 (1983) 62-64
4. Bergdahl I.A., Gerhardsson L., Schutz A., Desnick R.J., Wetmur J.G., and Skerfving S. Delta-aminolevulinic acid dehydratase polymorphism: influence on lead levels and kidney function in humans. Arch Environ Health 52 (1997) 91-96
5. Bernard S.M., and McGeehin M.A. Prevalence of blood lead levels >or=5 micro g/dL among US children 1 to 5 years of age and socioeconomic and demographic factors associated with blood of lead levels 5 to 10 micro g/dL, Third National Health and Nutrition Examination Survey, 1988-1994. Pediatrics 112 (2003) 1308-1313
6. Brennan, MJW, Cantrill RC. [delta]-Aminolaevulinic acid is a potent agonist for GABA autoreceptors. Nature 1979;280:514-5.
7. Carter-Pokras O., and Baquet C. What is a health disparity?. Public Health Rep 117 (2002) 426-434
8. Centers for Disease Control and Prevention; 2009.
9. City of El Paso, Texas; 2008.
10. Davis D.W., Chang F., Burns B., Robinson J., and Dossett D. Lead exposure and attention regulation in children living in poverty. Dev Med Child Neurol 46 (2004) 825-831
11. Demasi M., Penatti C.A.A., Delucia R., and Bechara E.J.H. The prooxidant effect of 5-aminolevulinic acid in the brain tissue of rats: implications in neuropsychiatric manifestations in porphyrias. Free Radic Biol Med 20 (1996) 291-299
12. Emanuelli T., Pagel F.W., Porciúncula L.O., and Souza D.O. Effects of 5-aminolevulinic acid on the glutamatergic neurotransmission. Neurochem Int 42 (2003) 115-121
13. Feeney R, Zink E. Review of the performance characteristics of the LeadCare II Blood Lead Testing System; 2006.
14. Finkelstein Y., Markowitz M.E., and Rosen J.F. Low-level lead-induced neurotoxicity in children: an update on central nervous system effects. Brain Res Rev 27 (1998) 168-176
15. Fleming D.E., Chettle D.R., Wetmur J.G., Desnick R.J., Robin J.P., Boulay D., et al. Effect of the delta-aminolevulinate dehydratase polymorphism on the accumulation of lead in bone and blood in lead smelter workers. Environ Res 77 (1998) 49-61
16. Fry R, Gonzales F. Pew Hispanic Center, Washington, DC; 2008. p. 1-28.
17. Hu Y., Shen H., Keep R.F., and Smith D.E. Peptide transporter 2 (PEPT2) expression in brain protects against 5-aminolevulinic acid neurotoxicity. J Neurochem 103 (2007) 2058-2065
18. Jusko T., Henderson C., Lanphear B., Cory-Slechta D., Parsons P., and Canfield R. Blood lead concentrations <10 micro g/dL and child intelligence at 6 years of age. Environ Health Perspect 116 (2008) 243-248
19. Ketter ME. The ASARCO El Paso smelter: a source of local contamination of soils in El Paso (Texas), Cuidad Juárez (Chihuahua, Mexico), and Anapra (New Mexico); 2006.
20. Klaassen C.D. Heavy metals and heavy-metal antagonists. In: Brunton L.L., Lazo J.S., and Parker K.L. (Eds). Goodman & Gilman's the phamacological basis of therapeutics (2006), McGraw Hill, New York 1753-1775
21. Lanphear B.P., Dietrich K., Auinger P., and Cox C. Cognitive deficits associated with blood lead concentrations <10 micro g/dL in US children and adolescents. Public Health Rep 115 (2000) 521-529
22. Lindberg R.L.P., Martini R., Baumgartner M., Erne B., Borg J., Zielasek J., et al. Motor neuropathy in porphobilinogen deaminase-deficient mice imitates the peripheral neuropathy of human acute porphyria. J Clin Invest 103 (1999) 1127-1134
23. Liu R., Tang A., Tan Y., Limenta L., and Lee E. Interethnic differences of PEPT2 (SLC15A2) polymorphism distribution and associations with cephalexin pharmacokinetics in healthy Asian subjects. Eur J Clin Pharmacol 65 (2009) 65-70
24. Mobidity and Mortality Weekly Report. Atlanta: Center for Disease Control and Prevention; 2000. p. 1-13.
25. Ocheltree S.M., Shen H., Hu Y., Keep R.F., and Smith D.E. Role and relevance of peptide transporter 2 (PEPT2) in the kidney and choroid plexus: in vivo studies with glycylsarcosine in wild-type and PEPT2 knockout mice. J Pharmacol Exp Ther 315 (2005) 240-247
26. Pérez-Bravo F, Ruz M, Morán-Jiménez MJ, Olivares M, Rebolledo A, Codoceo J, et al. Association between aminolevulinate dehydrase genotypes and blood lead levels in children from a lead-contaminated area in Antofagasta, Chile. Arch Environ Contam Toxicol 2004;47:276-80.
27. Petrucci R., Leonardi A., and Battistuzzi G. The genetic polymorphism of delta-aminolevulinic acid dehydratase in Italy. Hum Genet 60 (1982) 289-290
28. Pierach C.A., and Edwards P.S. Neurotoxicity of δ-aminolevulinic acid and porphobilinogen. Exp Neurol 62 (1978) 810-814
29. Pinsonneault J., Nielsen C.U., and Sadee W. Genetic variants of the human H+/dipeptide transporter PEPT2: analysis of haplotype functions. J Pharmacol Exp Ther 311 (2004) 1088-1096 [Epub 2004 July 1028]
30. Ramamoorthy S., Liu W., Ma Y.-Y., Yang-Feng T.L., Ganapathy V., and Leibach F.H. Proton/peptide cotransporter (PEPT 2) from human kidney: functional characterization and chromosomal localization. Biochim Biophys Acta (BBA)-Biomembr 1240 (1995) 1-4
31. Rubio-Aliaga I., Frey I., Boll M., Groneberg D.A., Eichinger H.M., Balling R., et al. Targeted disruption of the peptide transporter Pept2 gene in mice defines its physiological role in the kidney. Mol Cell Biol 23 (2003) 3247-3252
32. Schwartz B.S., Lee B.K., Stewart W., Ahn K.D., Springer K., and Kelsey K. Associations of delta-aminolevulinic acid dehydratase genotype with plant, exposure duration, and blood lead and zinc protoporhyrin levels in Korean lead workers. Am J Epidemiol 142 (1995) 738-745
33. Secchi G.C., Erba L., and Cambiaghi G. delta-Aminolevulinic acid dehydratase activity of erythrocytes and liver tissue in man. Arch Environ Health 28 (1974) 130-132
34. Shen H., Smith D.E., Yang T., Huang Y.G., Schnermann J.B., and Brosius III F.C. Localization of PEPT1 and PEPT2 proton-coupled oligopeptide transporter mRNA and protein in rat kidney. Am J Physiol Renal Physiol 276 (1999) F658-665
35. Shen X.M., Wu S.H., Yan C.H., Zhao W., Ao L.M., Zhang Y.W., et al. Delta-aminolevulinate dehydratase polymorphism and blood lead levels in Chinese children. Environ Res 85 (2001) 185-190
36. Shen H., Smith D.E., Keep R.F., Xiang J., and Brosius F.C. Targeted disruption of the PEPT2 gene markedly reduces dipeptide uptake in choroid plexus. J Biol Chem 278 (2003) 4786-4791
37. Silbergeld E.K., Waalkes M., and Rice J.M. Lead as a carcinogen: experimental evidence and mechanisms of action. Am J Ind Med 38 (2000) 316-323
38. Villayandre B.M., Paniagua M.A., Fernandez-Lopez A., and Calvo P. Effect of delta-aminolevulinic acid treatment on N-methyl-d-aspartate receptor at different ages in the rat brain. Brain Res 1061 (2005) 80-87
39. Wang L., Yan D., Gu Y., Sun L.-G., and Ruan D.-Y. Effects of extracellular-aminolaevulinic acid on sodium currents in acutely isolated rat hippocampal CA1 neurons. Eur J Neurosci 22 (2005) 3122-3128
40. Wetmur J.G., Kaya A.H., Plewinska M., and Desnick R.J. Molecular characterization of the human delta-aminolevulinate dehydratase 2 (ALAD2) allele: implications for molecular screening of individuals for genetic susceptibility to lead poisoning. Am J Hum Genet 49 (1991) 757-763
41. Wetmur J.G., Lehnert G., and Desnick R.J. The delta-aminolevulinate dehydratase polymorphism: higher blood lead levels in lead workers and environmentally exposed children with the 1-2 and 2-2 isozymes. Environ Res 56 (1991) 109-119
42. Witzmann F.A., Fultz C.D., Grant R.A., Wright L.S., Kornguth S.E., and Siegel F.L. Regional protein alterations in rat kidneys induced by lead exposure. Electrophoresis 20 (1999) 943-951
43. Workgroup to the Advisory Committee on Childhood Lead Poisoning Prevention. Atlanta: Center for Disease Control and Prevention; 2004.
44. Ziemsen B., Angerer J., Lehnert G., Benkman H.G., and Goedde H.W. Polymorphism of delta-aminolevulinic acid deydratase in lead exposed workers. Int Arch Occup Enviorn Health 58 (1986) 245-247